7645 Background: In patients (pts) with relapsed NSCLC, erlotinib 150 mg/d significantly
prolonged survival, delayed symptom progression, and improved quality of life versus …

19000 Background: Erlotinib significantly improved survival and quality of life while delaying
symptom progression compared with placebo in patients (pts) with relapsed NSCLC …

18018 Background: Erlotinib significantly improved survival versus placebo and was well
tolerated in patients (pts) with previously treated advanced NSCLC in the phase III BR. 21 …

Background: Erlotinib is proven to prolong survival, delay symptom progression and improve
quality of life for pts with advanced NSCLC (Shepherd et al. N Engl J Med 2005; 353: 123 …

7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …

Background: A randomized trial carried out by Shepherd et al. in patients with advanced or
metastatic non-small-cell lung cancer showed statistically significant benefit of erlotinib over …

BACKGROUND: Erlotinib demonstrated significantly prolonged survival versus placebo in
patients with advanced NSCLC who had progressed after standard chemotherapy. TRUST …

Erlotinib is a highly potent inhibitor of epidermal growth factor receptor tyrosine-kinase
activity that significantly prolongs overall survival in patients with non-small-cell lung cancer …

Aims: The efficacy of erlotinib (Tarceva, Roche Products, Dee Why, Australia) has been
demonstrated in patients with advanced non‐small‐cell lung cancer (NSCLC). Tarceva lung …

Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …